Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Gyula Ostoros"'
Autor:
Zoltán Kiss, Tamás G. Szabó, Csaba Polgár, Zsolt Horváth, Péter Nagy, Ibolya Fábián, Valéria Kovács, György Surján, Zsófia Barcza, István Kenessey, András Wéber, István Wittmann, Gergő Attila Molnár, Eszter Gyöngyösi, Angéla Benedek, Eugenia Karamousouli, Zsolt Abonyi-Tóth, Renáta Bertókné Tamás, Diána Viktória Fürtős, Krisztina Bogos, Judit Moldvay, Gabriella Gálffy, Lilla Tamási, Veronika Müller, Zoárd Tibor Krasznai, Gyula Ostoros, Zsolt Pápai-Székely, Anikó Maráz, Gabriella Branyiczkiné Géczy, Lászlóné Hilbert, Láśzló Tamás Berki, György Rokszin, Zoltán Vokó
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe nationwide HUN-CANCER EPI study examined cancer incidence and mortality rates in Hungary from 2011 to 2019.MethodsUsing data from the National Health Insurance Fund (NHIF) and Hungarian Central Statistical Office (HCSO), our retrospecti
Externí odkaz:
https://doaj.org/article/03adbbbd3d054b19a967d6a6c292c818
Autor:
Zolta´n Kiss, Krisztina Bogos, Lilla Tamási, Gyula Ostoros, Veronika Müller, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Kata Knollmajer, Máté Várnai, Krisztina Kovács, Andrea Berta, István Köveskuti, Eugenia Karamousouli, György Rokszin, Zsolt Abonyi-Tóth, Zsófia Barcza, István Kenessey, András Weber, Péter Nagy, Petra Freyler-Fadgyas, Miklós Szócska, Péter Szegner, Lászlóné Hilbert, Gabriella Branyiczkiné Géczy, György Surján, Judit Moldvay, Zoltán Vokó, Gabriella Gálffy, Zoltán Polányi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
ObjectiveThe Hungarian Undiagnosed Lung Cancer (HULC) study aimed to explore the potential reasons for missed LC (lung cancer) diagnosis by comparing healthcare and socio-economic data among patients with post-mortem diagnosed LC with those who were
Externí odkaz:
https://doaj.org/article/dc1a39dc32514d11b8d8fffbd26a0f45
Autor:
Zsuzsa S. Kocsis, Gyöngyi Farkas, András Bajcsay, Márta Kun-Gazda, József Lövey, Gyula Ostoros, Tamás Pócza, András Herein, Katalin Ladányi, Gábor Székely, Zsolt Markóczy, Zoltán Takácsi-Nagy, Csaba Polgár, Zsolt Juranyi
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Due to the profound difference in radiosensitivity of patients and various side effects caused by this phenomenon, a radiosensitivity marker is needed. Prediction by a marker may help personalise the treatment. In this study, we tested chromosomal ab
Externí odkaz:
https://doaj.org/article/e3c230458481433faae4e161f5e78458
Autor:
Zsolt Markóczy, Veronika Sárosi, Iveta Kudaba, Gabriella Gálffy, Ülkü Yilmaz Turay, Ahmet Demirkazik, Gunta Purkalne, Attila Somfay, Zsolt Pápai-Székely, Erzsébet Rásó, Gyula Ostoros
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine clinical
Externí odkaz:
https://doaj.org/article/d7176d935e0a4a359302b37df3fb11e5
Autor:
Krisztina Bogos, Zoltán Kiss, Gabriella Gálffy, Lilla Tamási, Gyula Ostoros, Veronika Müller, László Urbán, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Zoltán Polányi, Zsófia Nagy-Erdei, Zoltán Vokó, Balázs Nagy, Krisztián Horváth, György Rokszin, Zsolt Abonyi-Tóth, Judit Moldvay
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Objective: While Hungary is often reported to have the highest incidence and mortality rates of lung cancer, until 2018 no nationwide epidemiology study was conducted to confirm these trends. The objective of this study was to estimate the occurrence
Externí odkaz:
https://doaj.org/article/6ffedb1a368b4ae282becbb0fa3e0fa8
Autor:
Zoltan Lohinai, Peter Dome, Zsuzsa Szilagyi, Gyula Ostoros, Judit Moldvay, Balazs Hegedus, Balazs Dome, Glen J Weiss
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0144797 (2016)
Based on in vitro data and results of a recent drug repositioning study, some medications approved by the FDA for the treatment of various non-malignant disorders were demonstrated to have anti-SCLC activity in preclinical models. The aim of our stud
Externí odkaz:
https://doaj.org/article/f273bed2e65542a6ad99a3e82db83c2a
Publikováno v:
Current opinion in oncology. 35(1)
Small cell lung cancer (SCLC) is marked by an exceptionally high proliferative rate and poor prognosis. Given its high propensity to metastasize, nearly two-thirds of SCLC patients are diagnosed with extensive-stage (ES) disease when surgery is not a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4925aed39f76ae8dc905b06b7db131e8
https://pubmed.ncbi.nlm.nih.gov/36420570
https://pubmed.ncbi.nlm.nih.gov/36420570
Autor:
Zoltán Kiss, Krisztina Bogos, Lilla Tamási, Gyula Ostoros, Veronika Müller, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Kata Knollmajer, Máté Várnai, Krisztina Kovács, Andrea Berta, István Köveskuti, Eugenia Karamousouli, György Rokszin, Zsolt Abonyi-Tóth, Zsófia Barcza, István Kenessey, András Weber, Péter Nagy, Petra Freyler-Fadgyas, Miklós Szócska, Péter Szegner, Lászlóné Hilbert, Gabriella Branyiczkiné Géczy, György Surján, Judit Moldvay, Zoltán Vokó, Gabriella Gálffy, Zoltán Polányi
Publikováno v:
Frontiers in oncology. 12
ObjectiveThe Hungarian Undiagnosed Lung Cancer (HULC) study aimed to explore the potential reasons for missed LC (lung cancer) diagnosis by comparing healthcare and socio-economic data among patients with post-mortem diagnosed LC with those who were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d723510e3a37a4800efac82cd453675
https://pubmed.ncbi.nlm.nih.gov/36505881
https://pubmed.ncbi.nlm.nih.gov/36505881
Autor:
Lilla Tamási, Laszlo Urban, György Rokszin, Zsolt Abonyi-Tóth, Zoltán Kiss, Gyula Ostoros, Zsófia Nagy-Erdei, Zoltán Polányi, Judit Moldvay, Krisztián Horváth, Veronika Müller, Krisztina Bogos, Gabriella Gálffy, Zoltán Vokó, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Balázs Nagy, Zsófia Barcza
Publikováno v:
Journal of Thoracic Oncology. 15:692-699
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fb798d5c14d6861fb6b67ca2c90a53
https://doi.org/10.1016/j.jtho.2019.11.001
https://doi.org/10.1016/j.jtho.2019.11.001
Autor:
Gyula Ostoros
Publikováno v:
Lege Artis Medicinae. 30:515-519
Az elmúlt 30 évben a tüdőrák komplex kezelésében óriási fejlődés történt. Ez a fejlődés főként az utóbbi évtizedhez köthető. A tüdőrák kezelésével kapcsolatos nihilizmus már a múlté, realitássá vált az is, hogy az elő
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8419b507bda3f5c36e107caa6e2a245
https://doi.org/10.33616/lam.30.041
https://doi.org/10.33616/lam.30.041